The JAMA Oncology publication provides strong clinical validation for PDS0101, but the company is not advancing it internally to Phase 3 — instead seeking a partner. The Nant Capital PIPE and exclusive negotiation right signal potential near-term deal activity. Watch for partnership announcement or NantWorks license exercise within the one-year window.
Price Chart
Executive Summary
PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology showing 39.3-month median overall survival in ICI-naïve HPV16-positive HNSCC patients (vs 17.9 months for standard-of-care pembrolizumab) and a 36% ORR (vs 19% SOC). The company also disclosed a PIPE financing of up to $22.3M led by Nant Capital and a one-year exclusive negotiation right for PDS0101 with NantWorks. The data is clinically compelling but the company is prioritizing PDS0301 in mCRC and seeking a partner for PDS0101 Phase 3, creating execution risk.
Key Financial Metrics
Key Facts
- Phase 2 VERSATILE-002 published in JAMA Oncology: 39.3-month median OS in ICI-naïve CPS≥1 patients vs 17.9 months SOC pembrolizumab
- ORR 36% (investigator review) vs 19% SOC pembrolizumab; 5/53 complete responders by investigator review
- Grade ≥3 TRAEs 13.8% vs 17% SOC pembrolizumab; no Grade 5 events
- Company announced initial closing of PIPE financing up to $22.3M led by Nant Capital
- NantWorks granted one-year exclusive right to negotiate an exclusive license to PDS0101
- Company prioritizing PDS0301 in mCRC while pursuing partnership for PDS0101 Phase 3 development
Financial Impact
PIPE financing of up to $22.3M led by Nant Capital; no revenue or EPS disclosed
Risk Factors
- Company is not funding PDS0101 Phase 3 internally — partnership-dependent for value realization
- PIPE financing of up to $22.3M may cause dilution; terms not disclosed
- PDS0301 in mCRC is earlier-stage and carries clinical risk
- No head-to-head trial data — cross-trial comparisons have inherent limitations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366230 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 3 | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.30 (+4.84%) |
Oct 20, 2026 7d ago | 8-K | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.30 (+4.84%) |
Oct 20, 2026 7d ago | 8-K | $0.9605 $1.24 | ▲ +29.10% | ▲ +28.57% | $1.30 (+35.35%) |
Oct 14, 2026 13d ago | S-3 | $1.30 $1.13 | ▲ +13.08% | ▲ +11.97% | $1.30 (+0.00%) |
Oct 6, 2026 21d ago | 8-K | $1.05 $1.07 | ▲ +1.91% | ▲ +2.15% | $1.30 (+24.40%) |
Sep 22, 2026 5w ago | 8-K | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.30 (+42.86%) |
Sep 22, 2026 5w ago | Press Release | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.30 (+42.86%) |
Sep 21, 2026 5w ago | SC 13D | $0.9100 $0.8240 | ▼ −9.45% | ▼ −8.73% | $1.30 (+42.86%) |
Sep 4, 2026 7w ago | 8-K | $0.3000 $0.2930 | ▲ +2.33% | ▲ +1.87% | $1.30 (−333.33%) |
Aug 19, 2026 9w ago | 8-K | $0.2089 $0.2185 | ▲ +4.60% | ▲ +4.19% | $1.30 (+522.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers